Genomic Health, Inc.
301 Penobscot Drive
About Genomic Health, Inc.About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
About Oncotype DX® The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
404 articles about Genomic Health, Inc.
Genomic Health Announces 2017 Fourth Quarter and Year-end Financial Results, Provides 2018 Financial Outlook
Achieved $1.9M Profit in the Fourth Quarter; Reported Net Loss of $3.9M for the Full Year Delivered $0.4M Full-year Profit on a Non-GAAP Basis Excluding Business Development Transaction Costs Delivered 7 Percent Test Growth and 6 Percent Revenue Growth in the Fourth Quarter Guides to Double-digit Revenue Growth and Full-year Profitability in 2018
Genomic Health Expands Offering to Prostate Cancer Patients with Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test to Predict Treatment Response in Metastatic Disease
New Liquid Biopsy Test Helps Physicians Select Most Effective Treatment, Prolonging Lives of Men with Metastatic Castration-resistant Prostate Cancer
Genomic Health Release: Oncotype DX Genomic Prostate Score Test Increases Use of Active Surveillance by 30 Percent in Low-Risk Patients, Resulting in Greater Adherence to Guideline-Based Care
Results of this large, independently conducted study, published in Reviews in Urology, bring the collective published clinical utility evidence to four studies in nearly 8,300 men, demonstrating the actionable impact of the GPS test in treatment planning.
Genomic Health: New Validation Shows Oncotype DX Breast Recurrence Score Test Predicts Clinical Response to Neoadjuvant Hormonal Therapy to Improve Surgical Outcomes in Certain Patients with Large Tumors
Genomic Health today announced highlights from new data presentations with the Oncotype DX Breast Recurrence Score test at the 2017 SABCS.
Genomic Health Presents New Data Demonstrating Value of Oncotype DX to Optimize Breast Cancer Outcomes and Reduce Treatment Burden Throughout Disease Continuum
The analysis demonstrated that Recurrence Score results significantly predicted the likelihood of clinical response to neoadjuvant therapy.
Genomic Health Announces Research Collaboration With Janssen to Evaluate the Oncotype DX Genomic Prostate Score Test for Potential Drug Development
As part of the agreement, Genomic Health will test samples from Janssen studies to examine the association of GPS results with clinical outcomes.
Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests
Initial efforts under this agreement will focus on Genomic Health's development of a high-PSA reflex test to accurately predict the presence of high-grade cancer prior to prostate biopsy.
Total revenue was $83.8 million in the third quarter of 2017, compared with $82.3 million in the third quarter of 2016.
Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
The call and webcast will follow the release of the third quarter financial results after market close.
Genomic Health And Biocartis Announce Agreement To Develop An Idylla IVD Oncotype DX Breast Cancer Test To Broaden Global Patient Access
Genomic Health Release: New Analysis From German Study Group Prospective Trial Shows Minimal Distant Recurrence In Patients With Clinically High-Risk Breast Cancer And Low Oncotype DX Breast Recurrence Score® Results Following Five Years Of Hormone Therap
Genomic Health Presents Data Demonstrating Importance Of Oncotype DX Breast Recurrence Score Test In Predicting Outcomes Across Patient Populations At ESMO 2017
Genomic Health Continues To Pioneer Genomic-Based Cancer Diagnostics With Multiple Presentations At ESMO 2017 Congress
Genomic Health To Announce Second Quarter 2017 Financial Results And Host Conference Call On Tuesday, August 1, 2017
Genomic Health Release: Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role Of Genomic Testing In Treatment Of Early Breast Cancer
Genomic Health: New Data Show Important Role Of Genomic Testing In Treatment Of Older Breast Cancer Patients
Genomic Health Presents Data Further Demonstrating Ability Of Oncotype DX Tests To Optimize Outcomes In Patients Across Cancer Types
Genomic Health Release: Prospective Oncotype DX Genomic Prostate Score Test Data Presented At American Urological Association And Published In Urology Establish Test's Ability To Increase Use And Persistence On Active Surveillance In Prostate Cancer Patie